Abstract
24 patients with 28 brain metastases were treated with fractionated stereotactic radiotherapy (SRT). Doses ranged from 10 Gy in two fractions to 20 Gy in two fractions. 13 patients received SRT boost after whole brain radiotherapy (WBRT), 5 were treated with SRT alone and 6 were treated at the time of recurrence following WBRT. The median progression-free survival at the treated site was 18 months and the median survival was 18 months. All patients were treated without admission to hospital. Toxicity of fractionated SRT was minimal and patients treated without WBRT did not suffer significant alopecia. Fractionated SRT offers a non-toxic noninvasive alternative to excision surgery in patients with solitary brain metastases. The optimum fractionation schedule and the role of whole brain irradiation remain to be determined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
